Formal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugs
FDA issued final guidance on formal meetings for OTC monograph drug sponsors, clarifying procedures and expectations. No immediate regulatory changes, but impacts planning for OTC drug development and FDA interactions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Sponsors and requestors of OTC monograph drugs, including branded, generic, and API manufacturers involved in OTC monograph products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline; apply to future meeting requests.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA finalized guidance on formal meeting processes for OTC monograph drugs, replacing draft guidance. Key changes include updated procedures for meeting requests, types of meetings, and documentation.
Who it affects
Sponsors and requestors of OTC monograph drugs, including branded, generic, and API manufacturers involved in OTC monograph products.
What you must do
Review the final guidance to align internal meeting request processes with FDA expectations.
Deadline
No specific deadline; apply to future meeting requests.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness